Management of Thalassemia with Severe Anemia

Transfusion Management

The American Heart Association recommends blood transfusion to maintain a pre-transfusion hemoglobin level of 9-10 g/dL and a post-transfusion level of 13-14 g/dL, with concurrent iron chelation therapy to prevent iron overload in patients with thalassemia and severe anemia (hemoglobin 7 g/dL) 1
Blood transfusion is the cornerstone of treatment for thalassemia major, aimed at suppressing ineffective erythropoiesis and improving quality of life 1
Maintain pre-transfusion hemoglobin levels at 9-10 g/dL to balance between minimizing iron loading and maximizing symptom relief 1
Post-transfusion hemoglobin should target 13-14 g/dL 1
Monitor hemoglobin levels every 2 weeks during treatment periods 2
All patients with severe anemia (hemoglobin lower than 8 g/dL) should receive RBC transfusion 3

Iron chelation therapy must be initiated concurrently with transfusion therapy to prevent complications of iron overload in patients with thalassemia 1
Deferoxamine is recommended during periods of antiviral treatment for hepatitis C 2
Deferiprone (use with caution as it may increase risk of neutropenia) 2
Monitor liver iron concentration (LIC) via MRI to guide chelation therapy intensity 2

Regular cardiac assessment is essential as cardiac complications from iron overload are a major cause of death in patients with thalassemia 1
Patients with cardiovascular diseases should be closely monitored, and those with decompensated myocardiopathy should be excluded from certain treatments 2
Monitor for hepatic complications, especially in patients with concurrent viral hepatitis 4, 5
Continuous monitoring of hematologic parameters to detect anemia and neutropenia 2

For thalassemia patients with HCV infection, treatment should follow the same rules as for HCV monoinfection 6
Combination therapy with Peg-interferon and ribavirin may be required, with careful monitoring of hemoglobin levels 5
Expect a 30-40% increase in transfusion requirements during HCV treatment 5, 6
Maintain hemoglobin levels above 9 g/dL during antiviral therapy 2

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative option for thalassemia major 7
HSCT is recommended for transfusion-dependent severe thalassemia, particularly in children aged 2-6 years before progression to stage 3 7

Failure to initiate iron chelation therapy concurrently with transfusion therapy can lead to iron overload and organ damage in patients with thalassemia 1
Switching between chelation agents may be necessary during certain treatments (e.g., switching to deferoxamine during HCV treatment) 2